Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Cash & Equivalents (2016 - 2025)

Jaguar Health (JAGX) has disclosed Cash & Equivalents for 11 consecutive years, with $968000.0 as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 87.9% to $968000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $968000.0 through Dec 2025, down 87.9% year-over-year, with the annual reading at $968000.0 for FY2025, 87.9% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $968000.0 at Jaguar Health, down from $3.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $32.2 million in Q1 2021, with the low at $968000.0 in Q4 2025.
  • Average Cash & Equivalents over 5 years is $11.0 million, with a median of $9.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 8211.86% in 2021, then crashed 87.9% in 2025.
  • Over 5 years, Cash & Equivalents stood at $17.1 million in 2021, then crashed by 67.93% to $5.5 million in 2022, then rose by 18.28% to $6.5 million in 2023, then grew by 23.7% to $8.0 million in 2024, then plummeted by 87.9% to $968000.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $968000.0, $3.5 million, and $2.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.